ArticleRheumatology and therapy2026
Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06418529 (Comparative Effectiveness of New Initiators of Tofacitinib and Other Biologic/Targeted Synthetic DMARDs in Patients With Rheumatoid Arthritis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effectiveness of New Initiators of Tofacitinib and Other Biologic/Targeted Synthetic DMARDs in Patients With Rheumatoid Arthritis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis new-user, active comparator study of patients with rheumatoid arthritis (RA) evaluated the real-world effectiveness of tofacitinib versus biologic disease-modifying antirheumatic drugs (bDMARDs) using data from the US OM1 PremiOM™ RA dataset.
methodsThis analysis included patients with RA aged ≥ 18 years initiating tofacitinib or bDMARDs (tumor necrosis factor inhibitors, TNFi; abatacept; interleukin-6 inhibitors, IL-6i) from January 1, 2013-March 13, 2024, with > 1 Clinical Disease Activity Index (CDAI) score in the 45 days prior to and including the index date. Propensity score weighting adjusted for differences in baseline characteristics between treatment groups. Crude incidence rates were calculated to estimate the first record of CDAI remission (CDAI ≤ 2.8) and low disease activity (LDA; CDAI ≤ 10.0) at 6 and 12 months. Cox regression was used to estimate weighted hazard ratios. Subgroup analyses assessed heterogeneity of treatment effects (HTE).
resultsThe final sample size across cohorts was 3681 (tofacitinib), 11,667 (TNFi), 3528 (abatacept), and 2464 (IL-6i). At baseline, the proportion of patients with observed RA disease duration ≥ 2 years was 48.7-70.0% across cohorts; use of 2/3/≥ 4 prior biologic/targeted synthetic (b/ts) DMARDs was 21.4%/10.2%/5.0% (tofacitinib), versus 8.1%/3.0%/2.4% (TNFi), 19.2%/8.3%/3.7% (abatacept), and 25.4%/13.7%/10.5% (IL-6i). In the overall and TNFi-experienced population, there were no statistically significant differences in CDAI remission and LDA rates between treatments at 6 and 12 months. Potential HTE was observed among subgroups of age ≥ 50 years, obesity, prior b/tsDMARD use, corticosteroid use, and Sjӧgren's disease.
conclusionAt 6 and 12 months, there were no significant differences in achieving or maintaining CDAI remission and LDA for tofacitinib versus TNFi, abatacept, and IL-6i among the overall and TNFi-experienced RA population in US clinical practice. Subgroup analyses suggest some potential HTE; however, interpretation is limited by the small number of outcome events. CLINICALTRIALS: GOV ID: NCT06418529.
Indexed as
Identifiers
42879079What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.